Prothena | PRTA - Ebitda


Prothena reported $25.98M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 139.22M 58.96M Jun/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Exelixis USD 258.29M 15.43M Mar/2026
Immunic USD -22.78M 753K Jun/2024
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Prothena USD 25.98M 65.51M Mar/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026